Detalles de la búsqueda
1.
Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study.
Lancet
; 393(10182): 1699-1707, 2019 04 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-30929895
2.
Efficacy and safety of the trastuzumab biosimilar candidate CT-P6.
Future Oncol
; 14(19): 1909-1919, 2018 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-29482364
3.
Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study.
Ann Rheum Dis
; 76(2): 346-354, 2017 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-27117698
4.
Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.
Ann Rheum Dis
; 76(2): 355-363, 2017 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-27130908
5.
Soluble CD25 is increased in patients with sepsis-induced acute kidney injury.
Nephrology (Carlton)
; 19(6): 318-24, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24646167
6.
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study.
Ann Rheum Dis
; 72(10): 1605-12, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23687259
7.
A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study.
Ann Rheum Dis
; 72(10): 1613-20, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23687260
8.
Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters.
MAbs
; 13(1): 1868078, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33557682
9.
Correction to: The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases.
Drugs
; 80(10): 1039-1040, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32488813
10.
The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases.
Drugs
; 80(2): 99-113, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-32002851
11.
Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer.
Cancer Chemother Pharmacol
; 83(3): 501-508, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30535535
12.
The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
Expert Rev Gastroenterol Hepatol
; 9 Suppl 1: 27-34, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26395532
13.
Biosimilars for the management of rheumatoid arthritis: economic considerations.
Expert Rev Clin Immunol
; 11 Suppl 1: S43-52, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26395836
Resultados
1 -
13
de 13
1
Próxima >
>>